ALSO NOTED: CollaGenex touts Oracea trials; Teva issues earnings alert; FDA staffers question Pulminiq; and much more...

> CollaGenex of Newton, Pennsylvania, is touting the outcomes of two Phase III trials of Oracea for rosacea. Release

> The postponed launch of Clarithromycin Extended Release Tablets has caused Teva Pharmaceuticals to lower its earnings projection. Its stock took a beating this morning. Story

> Regulators are questioning whether a small trial of Chiron's Pulminiq provided enough data to support its approval for preventing lung transplant rejections. FDA officials say the trial suffered from five major weaknesses, including its size. The trial involved 56 patients. Story

> Shares of Oscient Pharmaceuticals of Waltham, Massachusetts, surged this morning on the news that its pneumonia drug worked over a shorter period of time than currently indicated. Preliminary data from a late-stage trial for community-acquired pneumonia indicated that a five-day regimen of Factive was just as effective as a seven-day schedule. Release

> Altus Pharmaceuticals of Cambridge, Massachusetts, has completed a Phase I trial of ALTU-238, a recombinant human growth hormone, and plans to start a Phase II trial in adults with human growth hormone deficiency. Release

> Researchers studying a new vaccine for the deadly Ebola and Marburg virus report it was highly effective in preventing the disease in monkeys. If the vaccines work in human trials they may be available for wide use in five to six years. Another experimental vaccine for the viruses is scheduled to enter human trials this year. Story

> Chutes & Ladders: San Antonio-based Azaya Therapeutics has appointed Michael Dwyer as President and CEO. Release

> Novartis has partnered with East African Botanicals to produce a larger quantity of the anti-malarial ingredient Coartem. Story

And Finally... New drugs aimed at promoting better sleep will be advertised to a huge number of women who have a hard time falling asleep, and staying asleep. Story

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.